ストックスクリーナーアプリを入手
7.2501
5.89%
0.3701
前日終値:
$6.88
開ける：
$6.92
24時間の取引高:
142.25K
Relative Volume:
0.07
時価総額：
$546.82M
収益：
$3.64M
当期純損益:
$-87.37M
株価収益率:
-1.764
EPS:
-4.11
ネットキャッシュフロー:
$-86.46M
1週間 パフォーマンス:
-5.63%
1か月 パフォーマンス:
-29.68%
6か月 パフォーマンス:
+55.33%
1年 パフォーマンス:
+11.39%
1日の値動き範囲:
$6.90
$7.3519
1週間の範囲:
$6.68
$7.76
52週間の値動き範囲:
$4.01
$11.24
Verastem Inc Stock (VSTM) Company Profile
VSTM を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VSTM
Verastem Inc
|
7.26 | 518.20M | 3.64M | -87.37M | -86.46M | -4.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
478.26 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
797.49 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
424.87 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
813.01 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.59 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Verastem Inc Stock (VSTM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-16 | 再開されました | Cantor Fitzgerald | Overweight |
| 2025-04-10 | 開始されました | Jefferies | Buy |
| 2025-03-24 | 繰り返されました | H.C. Wainwright | Buy |
| 2024-12-31 | 繰り返されました | BTIG Research | Buy |
| 2024-09-30 | 開始されました | Guggenheim | Buy |
| 2023-11-21 | 再開されました | BTIG Research | Buy |
| 2023-09-27 | 開始されました | B. Riley Securities | Buy |
| 2023-06-15 | アップグレード | Mizuho | Neutral → Buy |
| 2022-09-07 | 再開されました | Alliance Global Partners | Buy |
| 2022-04-29 | 再開されました | Cantor Fitzgerald | Overweight |
| 2022-04-14 | 開始されました | RBC Capital Mkts | Outperform |
| 2022-03-09 | 開始されました | Truist | Buy |
| 2021-07-01 | 開始されました | Alliance Global Partners | Buy |
| 2021-05-24 | アップグレード | BTIG Research | Neutral → Buy |
| 2019-06-20 | ダウングレード | BTIG Research | Buy → Neutral |
| 2019-05-10 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2018-07-13 | 開始されました | BTIG Research | Buy |
| 2018-05-02 | 開始されました | Seaport Global Securities | Buy |
| 2018-03-08 | 開始されました | B. Riley FBR, Inc. | Buy |
| 2017-09-07 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-04-13 | 開始されました | Oppenheimer | Outperform |
| 2017-03-24 | 繰り返されました | H.C. Wainwright | Buy |
| 2015-09-29 | ダウングレード | Cantor Fitzgerald | Buy → Hold |
| 2015-09-29 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2015-09-29 | ダウングレード | Jefferies | Buy → Hold |
| 2015-09-29 | ダウングレード | Raymond James | Strong Buy → Outperform |
| 2015-09-28 | ダウングレード | Mizuho | Buy → Neutral |
| 2015-09-28 | ダウングレード | ROTH Capital | Buy → Neutral |
| 2015-09-09 | 開始されました | Raymond James | Strong Buy |
| 2015-05-12 | 繰り返されました | UBS | Buy |
| 2015-04-08 | 開始されました | H.C. Wainwright | Buy |
| 2015-01-23 | 繰り返されました | ROTH Capital | Buy |
| 2014-07-08 | 再開されました | Oppenheimer | Perform |
| 2014-02-11 | 開始されました | Mizuho | Buy |
すべてを表示
Verastem Inc (VSTM) 最新ニュース
What's Going On With Verastem Stock Friday?Verastem (NASDAQ:VSTM) - Benzinga
Verastem ends trial of Avmapki Fakzynja combo with Amgen's Lumakras in NSCLC - MSN
Verastem Ends Lung Cancer Trial, Reallocates Resources - Sahm
Verastem Oncology stock drops after hours after discontinuing a clinical trial in lung cancer - MSN
Verastem stock steady as Mizuho reiterates Outperform rating By Investing.com - Investing.com Canada
Verastem Shifts Focus to KRAS G12D and Pancreatic Programs - TipRanks
Verastem to discontinue Avmapki/Fakzynja combo in KRAS G12C-mutated NSCLC - The Pharma Letter
Verastem (VSTM) Halts Development of Avutometinib/Defactinib Com - GuruFocus
Verastem: Downgrading To Buy Based On RAMP-203 Setback In Targeting KRAS G12C NSCLC (VSTM) - Seeking Alpha
Amgen stock dips as Lumakras combo trial ends; MariTide data now the next watch - ts2.tech
Verastem (NASDAQ:VSTM) Shares Cross Above 200 Day Moving AverageShould You Sell? - MarketBeat
Verastem, TEN Holdings And 3 Stocks To Watch Heading Into Tuesday - Benzinga
Verastem Oncology (VSTM) Shifts Focus to Promising KRAS G12D Inh - GuruFocus
Calkins, Verastem CFO, sells $628 in shares By Investing.com - Investing.com South Africa
Verastem Oncology provides update on Ramp 203 phase 1/2 clinical trial - marketscreener.com
Verastem Oncology Stock Drops After Hours After Discontinuing A Clinical Trial In Lung Cancer - Stocktwits
Verastem to Discontinue RAMP 203 Clinical Trial in Lung Cancer After Interim Data Read - marketscreener.com
Verastem stock falls after discontinuing KRAS G12C lung cancer trial By Investing.com - Investing.com Nigeria
Verastem (VSTM) Shifts Focus to Promising KRAS G12D Inhibitor in Cancer Treatment - GuruFocus
Verastem stock falls after discontinuing KRAS G12C lung cancer trial - Investing.com
Verastem discontinues KRAS G12C lung cancer trial to focus on G12D - Investing.com Canada
Verastem Oncology Provides Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer - Business Wire
Calkins, Verastem CFO, sells $628 in shares - Investing.com India
Behavioral Patterns of VSTM and Institutional Flows - Stock Traders Daily
Verastem, Inc.'s (NASDAQ:VSTM) Stock Retreats 26% But Revenues Haven't Escaped The Attention Of Investors - 富途牛牛
Verastem, Inc.'s (NASDAQ:VSTM) Share Price Is Still Matching Investor Opinion Despite 26% Slump - simplywall.st
Is Verastem Inc a good long term investmentAI-Driven Market Analysis & Double Digit Wealth Tips - earlytimes.in
Will Verastem Inc. stock outperform Nasdaq indexJuly 2025 Final Week & Consistent Profit Trade Alerts - Улправда
Verastem (STU:2VS) EV-to-OCF : -3.85 (As of Dec. 20, 2025) - GuruFocus
Can Verastem Inc. stock surprise with earnings upsideQuarterly Portfolio Review & Low Risk Entry Point Guides - Улправда
Squarepoint Ops LLC Boosts Stake in Verastem, Inc. $VSTM - MarketBeat
Can Verastem Inc. stock sustain revenue growthJuly 2025 News Drivers & AI Powered Buy/Sell Recommendations - Улправда
Verastem, Inc. (NASDAQ:VSTM) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Mizuho maintains Verastem stock outperform with $9 target - MSN
Is Verastem Inc. stock vulnerable to regulatory risksQuarterly Growth Report & Low Risk High Win Rate Stock Picks - Улправда
Verastem streamlines leadership team amid strategic transition - MSN
Verastem, Inc. Announces Departure of Chief Operating Officer - TradingView — Track All Markets
Why Verastem Inc. stock could benefit from AI revolutionGDP Growth & Fast Exit Strategy with Risk Control - bolumsonucanavari.com
How Verastem Inc. (2VSA) stock moves in volatile trading sessionsJuly 2025 Patterns & Real-Time Buy Signal Alerts - Улправда
Will Verastem Inc. stock benefit from green energy trendsQuarterly Growth Report & Expert Approved Momentum Trade Ideas - Улправда
Insider Sell Alert: Brian Stuglik Sells Shares of Verastem Inc (VSTM) - GuruFocus
Dir Stuglik Surrenders 592 Of Verastem Inc [VSTM] - TradingView — Track All Markets
[Form 4] Verastem, Inc. Insider Trading Activity - Stock Titan
Verastem (VSTM) CEO sells 393 shares tied to RSU vesting - Stock Titan
Verastem (VSTM) director reports 283-share sale for RSU tax withholding - Stock Titan
RSI Check: Is Verastem Inc. stock a defensive play in 2025Earnings Overview Report & AI Enhanced Execution Alerts - ulpravda.ru
Verastem Oncology announces management changes - MSN
Guggenheim Keeps Their Buy Rating on Verastem (VSTM) - The Globe and Mail
Verastem Inc (VSTM) 財務データ
収益
当期純利益
現金流量
EPS
1.09%
大文字化:
|
ボリューム (24 時間):